Consun Pharmaceutical Group Limited reported to the Hong Kong Stock Exchange that it repurchased 90,000 ordinary shares on 25 June 2026. The shares were bought on-market at prices ranging from HK$12.81 to HK$12.85, with a volume-weighted average of HK$12.83, for a total consideration of approximately HK$1.16 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased from 839.36 million to 839.27 million shares. Treasury shares increased to 2.28 million, while the total number of issued shares remained unchanged at 841.55 million. The latest buyback represents 0.0107% of the company’s outstanding shares before the purchase.

The repurchase forms part of the mandate approved on 26 May 2026, which permits Consun Pharma to buy back up to 84.12 million shares. Cumulative repurchases under this mandate now stand at 1.94 million shares, equivalent to 2.30% of the company’s issued shares on the mandate date.

In accordance with Main Board Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares until 25 July 2026.